Anatara Lifesciences Ltd. (ASX: ANR) is an Australia-based life sciences company engaged in the development and commercialisation of evidence-based and innovative products for gastrointestinal health where there is a significant unmet need. ANR possesses expertise in developing products for human and animal health and is now focused on human gastrointestinal health products.
Bromelain is a mixture of proteases that helps in preventing the diarrhoea-causing organism from attaching to the small intestine and block inflammation and the secretory action of toxins which causes diarrhoea in animals and humans. Proteases are extracted from pineapple stems.
Detach is a leading non-antibiotic product of ANR that helps in controlling scour, a diarrhoeal disease, which has been licensed to a leading global animal health company, Zoetis Inc.
Earlier, ANR had conducted in vitro Proof of Concept (PoC) studies over its Gastrointestinal ReProgramming (GaRP) product which is a unique natural dietary supplement designed to restore and maintain a healthy human gut and microbiome by restoring balance to the gut microbiome; reducing gastrointestinal inflammation; promoting and supporting mucosal healing and restoring intestinal epithelial barrier integrity.
Today, ANR has reported that it has received positive efficacy data from the PoC studies. The Gastrointestinal ReProgramming supplement targets the detailed formulation components to the small intestine and colon where they can have their greatest drug effect.
Gastrointestinal diseases and disorders such as IBD (Inflammatory Bowel Disease), a Crohn’s disease and Ulcerative Colitis, and IBS (Irritable Bowel Syndrome) are characterised by an increase in increased intestinal permeability, pro-inflammatory bacteria, and inflammation.
Approx. 11% of the global population is affected by IBS as a result of which 50% of patients turn to dietary supplements and complementary medicines. More than 5 million patients are affected by IBD worldwide, of which 30-50% of patients turned to alternative and complementary medicines. To identify the potential role of GaRP in filling the unmet needs of IBS and IBD patients ANR consulted with gastroenterologists.
To evaluate the performance of GaRP formulation, Anatara used industry-standard in vitro gut models which demonstrated a reduced attachment and invasion of IBD and IBS pro-inflammatory bacteria into healthy gut cells by more than 95% while protecting and maintaining gut integrity. More than 85% of the production of pro-inflammatory proteins by inflammatory cells and gut was reduced.
ANR, further, plans to start the human clinical study for IBS in the 2H CY2019 which will be funded from the existing resources and will support the health claims. Moreover, by the end of July 2019, ANR will move its Gastrointestinal ReProgramming into the final stage of pre-clinical development for IBD with mouse pre-clinical studies.
Looking at Anatara Lifesciences Limited’s stock performance, it has generated a negative return of 24.24% during the past six months. It is currently trading at A$0.500 (at the close of the market on 07 February 2019) with no change in the price during the day’s performance. ANR has approx. 49.41 million shares outstanding with a market cap of circa A$24.71 million and 52-week high and low of A$1.785 and A$0.375 respectively.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.